Tarsus Pharmaceuticals vs Twist Bioscience
Tarsus Pharmaceuticals reported revenue of $451 million in fiscal 2025, 1.2 times Twist Bioscience's $377 million in fiscal 2025. Tarsus Pharmaceuticals' revenue grew 146.7% in its latest year, and Twist Bioscience's grew 20.3%. Tarsus Pharmaceuticals had an operating margin of -15.7%, against -36.2% at Twist Bioscience. Free cash flow was −$22 million at Tarsus Pharmaceuticals and −$76 million at Twist Bioscience. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.
Side by side
| Tarsus Pharmaceuticals | Twist Bioscience | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Sep 30, 2025 |
| Revenue | $451M | $377M |
| Revenue growth | 146.7% | 20.3% |
| Revenue growth a year, last 5 years | — | 33.1% |
| Gross margin | — | 50.7% |
| Operating margin | −15.7% | −36.2% |
| Net margin | −14.7% | −20.6% |
| Free cash flow | −$22M | −$76M |
| Free cash flow margin | −4.9% | −20.1% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 11.1% | 3.1% |
| Last close | $80.28 | $111.60 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $20.0 million | sold $126.1 million |
| Piotroski F-score | 4 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Tarsus PharmaceuticalsTwist Bioscience
Operating margin
Percent of revenue
Tarsus PharmaceuticalsTwist Bioscience
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Tarsus PharmaceuticalsTwist Bioscience
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Tarsus Pharmaceuticals and Twist Bioscience pages.